Literature DB >> 2060883

Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis.

F Mion1, B Napoleon, F Berger, M Chevallier, S Bonvoisin, L Descos.   

Abstract

Azathioprine hepatotoxicity has been described mainly in renal transplant recipients. Most reported cases are related to lesions of the venous system of the liver: peliosis hepatis, veno-occlusive disease of the liver, perisinusoidal fibrosis, and nodular regenerative hyperplasia of the liver. The most common clinical manifestation of these hepatic vascular lesions is portal hypertension. We present a case of nodular regenerative hyperplasia and perivenous fibrosis in a patient receiving azathioprine for multiple sclerosis. Histological abnormalities were similar to those described in renal transplant patients, and azathioprine was the only potential hepatotoxic agent present.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060883      PMCID: PMC1378897          DOI: 10.1136/gut.32.6.715

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

Review 1.  Liver disease in renal transplant recipients.

Authors:  J Sopko; S Anuras
Journal:  Am J Med       Date:  1978-01       Impact factor: 4.965

2.  The effect of Imuran and Azaserine on liver function tests in the dog. Its relation to the detection of graft rejection following liver transplantation.

Authors:  J J Haxhe; G P Alexandre; P J Kestens
Journal:  Arch Int Pharmacodyn Ther       Date:  1967-08

3.  Idiopathic portal hypertension (perisinusoidal fibrosis) after renal transplantation.

Authors:  C Nataf; G Feldmann; D Lebrec; C Degott; J M Descamps; B Rueff; J P Benhamou
Journal:  Gut       Date:  1979-06       Impact factor: 23.059

4.  Irreversible liver damage after azathioprine.

Authors:  Z Zarday; F J Veith; M L Gliedman; R Soberman
Journal:  JAMA       Date:  1972-11-06       Impact factor: 56.272

5.  Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation.

Authors:  P G Gerlag; J P van Hooff
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

6.  Antineoplastic agents and the liver.

Authors:  D B Ménard; C Gisselbrecht; M Marty; F Reyes; D Dhumeaux
Journal:  Gastroenterology       Date:  1980-01       Impact factor: 22.682

7.  Peliosis hepatis in recipients of renal transplants.

Authors:  C Degott; B Rueff; H Kreis; A Duboust; F Potet; J P Benhamou
Journal:  Gut       Date:  1978-08       Impact factor: 23.059

8.  Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations.

Authors:  N Y Haboubi; H H Ali; H L Whitwell; P Ackrill
Journal:  Am J Gastroenterol       Date:  1988-03       Impact factor: 10.864

9.  Treatment of psoriasis with azathioprine.

Authors:  A Du Vivier; D D Munro; J Verbov
Journal:  Br Med J       Date:  1974-01-12

10.  Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis.

Authors:  I R Wanless; T A Godwin; F Allen; A Feder
Journal:  Medicine (Baltimore)       Date:  1980-09       Impact factor: 1.889

View more
  9 in total

1.  Azathioprine induced liver injury: a case report.

Authors:  Narendra S Choudhary; Sachin Gupta; Yogesh K Chawla; Ajay Duseja; Radha K Dhiman; Ashim Das
Journal:  Dig Dis Sci       Date:  2012-04-22       Impact factor: 3.199

2.  Severe cholestasis due to azathioprine in Behcet's disease.

Authors:  Kadir Gisi; Murat Ispiroglu; Bulent Kantarceken; Hamide Sayar
Journal:  BMJ Case Rep       Date:  2019-03-31

3.  Azathioprine-induced severe cholestatic hepatitis in patient carrying TPMT*3C polymorphism.

Authors:  Chaker Ben Salem; Lynda Ben Salah; Colandane Belajouza; Kamel Bouraoui
Journal:  Pharm World Sci       Date:  2010-10-23

4.  Severe cholestasis due to adalimumab in a Crohn's disease patient.

Authors:  Edward Kim; Brian Bressler; David F Schaeffer; Eric M Yoshida
Journal:  World J Hepatol       Date:  2013-10-27

Review 5.  Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.

Authors:  Helen Tremlett; Joel Oger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

6.  Familial occurrence of nodular regenerative hyperplasia of the liver: a report on three families.

Authors:  J Dumortier; O Boillot; M Chevallier; F Berger; P Potier; P J Valette; P Paliard; J Y Scoazec
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

Review 7.  Azathioprine-induced hepatitis and cholestasis occurring 1 year after treatment.

Authors:  Jason Chertoff; Sabikha Alam; Michael Black; Islam Y Elgendy
Journal:  BMJ Case Rep       Date:  2014-12-03

8.  Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation.

Authors:  O Pappo; H Ramos; T E Starzl; J J Fung; A J Demetris
Journal:  Am J Surg Pathol       Date:  1995-02       Impact factor: 6.394

9.  Predicting in vivo anti-hepatofibrotic drug efficacy based on in vitro high-content analysis.

Authors:  Baixue Zheng; Looling Tan; Xuejun Mo; Weimiao Yu; Yan Wang; Lisa Tucker-Kellogg; Roy E Welsch; Peter T C So; Hanry Yu
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.